In the clinic, there was a case report describing that an advanced upper urinary tract urothelial carcinoma (UTUC) patient with FGFR3 c.746C>G (p.Ser249Cys) could make a complete response to immunotherapy with the monoclonal antibody pembrolizumab (41), but whether FGFR3 c.746C>G (p.Ser249Cys) might influence the treatment response of BC patients was totally unknown and worth further investigation. The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.